Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UCB prepares for Cimzia filing in axial spondyloarthritis and psoriatic arthritis

This article was originally published in Scrip

Executive Summary

UCB is to make US and EU regulatory submissions for Cimzia (certolizumab pegol) by the end of the year for axial spondyloarthritis (AxSpA) including ankylosing spondylitis (AS), after reporting positive top-line Phase III results for the drug in these indications.



Related Companies